Merck (26)
- Business Finance (16)
- Human Resources (8)
- Uncategorized (2)
- Form of restricted stock unit terms for 2022 annual grants under the Merck & Co., Inc. 2019 Incentive Stock Plan (Filed With SEC on February 25, 2022)
- 2.900% Notes due 2061 Officers Certificate of the Company dated December 10, 2021, including form of the 2061 Notes (Filed With SEC on December 10, 2021)
- Merck & Co., Inc. Deferral Program Including the Base Salary Deferral Plan (Amended and Restated effective December 1, 2019) (Filed With SEC on February 26, 2020)
- Form of stock option terms for 2022 annual non-qualified option grants under the Merck & Co., Inc. 2019 Incentive Stock Plan (Filed With SEC on February 25, 2022)
- Merck & Co., Inc. Plan for Deferred Payment of Directors Compensation (Amended and Restated effective as of January 1 (Filed With SEC on February 25, 2022)
- 2.750% Notes due 2051 Officers Certificate of the Company dated December 10, 2021, including form of the 2051 Notes (Filed With SEC on December 10, 2021)
- 2.150% Notes due 2031 Officers Certificate of the Company dated December 10, 2021, including form of the 2031 Notes (Filed With SEC on December 10, 2021)
- 1.900% Notes due 2028 Officers Certificate of the Company dated December 10, 2021, including form of the 2028 Notes (Filed With SEC on December 10, 2021)
- 1.700% Notes due 2027 Officers Certificate of the Company dated December 10, 2021, including form of the 2027 Notes (Filed With SEC on December 10, 2021)
- Description of the Registrants 1.125% Notes due 2021, 1.875% Notes due 2026, and 2.500% Notes due 2034 (Filed With SEC on February 25, 2021)
- Form of stock option terms for 2021 annual non-qualified option grants under the Merck & Co., Inc. 2019 Incentive Stock Plan (Filed With SEC on February 25, 2021)
- Form of restricted stock unit terms for 2021 annual grants under the Merck & Co., Inc. 2019 Incentive Stock Plan (Filed With SEC on February 25, 2021)
- Description of the Registrants 0.500% Notes due 2024 and 1.375% Notes due 2036 (Filed With SEC on February 25, 2021)
- Description of the Registrants Common Stock (Filed With SEC on February 25, 2021)
- 2.450% Notes due 2050 Officers Certificate of the Company dated June 24, 2020, including form of the 2050 Notes (Filed With SEC on June 24, 2020)
- 2.350% Notes due 2040 Officers Certificate of the Company dated June 24, 2020, including form of the 2040 Notes (Filed With SEC on June 24, 2020)
- 1.450% Notes due 2030 Officers Certificate of the Company dated June 24, 2020, including form of the 2030 Notes (Filed With SEC on June 24, 2020)
- 0.750% Notes due 2026 Officers Certificate of the Company dated June 24, 2020, including form of the 2026 Notes (Filed With SEC on June 24, 2020)
- Merck & Co., Inc. Plan for Deferred Payment of Directors Compensation (Amended and Restated effective as of January 1, 2020) (Filed With SEC on February 26, 2020)
- 4.000% Notes due 2049 Officers Certificate of the Company dated March 7, 2019, including form of the 2049 Notes (Filed With SEC on March 7, 2019)
- 3.900% Notes due 2039 Officers Certificate of the Company dated March 7, 2019, including form of the 2039 Notes (Filed With SEC on March 7, 2019)
- 3.400% Notes due 2029 Officers Certificate of the Company dated March 7, 2019, including form of the 2029 Notes (Filed With SEC on March 7, 2019)
- 2.900% Notes due 2024 Officers Certificate of the Company dated March 7, 2019, including form of the 2024 Notes (Filed With SEC on March 7, 2019)
- Severance Agreement and General Release between Merck & Co., Inc. and Adam H. Schechter, dated December 1, 2018 (Filed With SEC on February 27, 2019)
- Offer Letter between Merck & Co., Inc. and Jennifer Zachary, dated March 16, 2018 (Filed With SEC on February 27, 2019)
- Merck & Co., Inc. U.S. Separation Benefits Plan (amended and restated as of January 1, 2019) (Filed With SEC on February 27, 2019)
